Exenatide

( DrugBank: Exenatide / KEGG DRUG: Exenatide )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease10
17Multiple system atrophy2
78Hypopituitarism2
IDDisease name (Link within this page)Number of trials
193Prader-Willi syndrome3
233Wolfram syndrome1

6. Parkinson disease


Clinical trials : 2,586Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

17. Multiple system atrophy


Clinical trials : 142Drugs : 142 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 110 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

78. Hypopituitarism


Clinical trials : 34Drugs : 44 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 19 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

193. Prader-Willi syndrome


Clinical trials : 128Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

233. Wolfram syndrome


Clinical trials : 12Drugs : 14 - (DrugBank : 6) / Drug target genes : 3 - Drug target pathways : 6 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries